Browse by author
Lookup NU author(s): Dr James Roberts
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Purpose: To compare long-term survival in patients with locally advanced and metastatic transitional cell carcinoma (TCC) of the urothelium treated with gemcitabine plus cisplatin (GC) or methotrexate/vinblastine/doxorubicin/cisplatin (MVAC). Patients and methods: Efficacy data from a large randomized phase III study of GC versus MVAC were updated. Time-to-event analyses were performed on the observed distributions of overall survival time and progression-free survival. Results: Four hundred and five patients were randomized, 203 to the GC arm and 202 to the MVAC arm. At the time of this analysis, 347 patients have died (GC 176, MVAC 171). Overall survival was similar in both arms (HR 1.09; 95% confidence interval [CI] 0.88-1.34, P = 0.66) with a median survival of 14.0 months (95% CI 12.3-15.5 months) in the GC, and 15.2 months (95% CI 13.2-17.3 months) in the MVAC arm. The median progression-free survival was 7.7 months with GC (95% CI 6.8-8.8) and 8.3 months with MVAC (95% CI 7.3-9.7) with a HR of 1.09 (95% CI 0.89-1.34). Significant prognostic factors favoring overall survival included performance status (> 70), TNM staging (M0 vs. M1), low/normal alkaline phosphatase expression, number of sites of disease < 3, and the absence of visceral metastasis. By adjusting for these prognostic factors, the HR was 0.99 for overall survival and 1.01 for progression-free survival. Conclusions: Long-term overall and progression-free survival following treatment with GC or MVAC are similar. These results strengthen the role of GC as a standard of care in patients with locally advanced and metastatic transitional-cell carcinoma (TCC).
Author(s): Roberts JT, von der Maase H, Sengelov L, Conte PF, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M
Publication type: Conference Proceedings (inc. Abstract)
Publication status: Published
Conference Name: Annals of Oncology: Workshop on Gemcitabine - Ten Years of Clinical Experience
Year of Conference: 2006
Pages: V118-V122
ISSN: 0923-7534
Publisher: Oxford University Press
URL: http://dx.doi.org/10.1093/annonc/mdj965
DOI: 10.1093/annonc/mdj965
Library holdings: Search Newcastle University Library for this item
ISBN: 15698041
